Sign in

Alessio Ciulli

@alessiociulli.bsky.social
693 followers 205 following 32 posts

Professor, Founder and Director of the Centre for Targeted Protein Degradation at the University of Dundee. We develop molecules that induce protein interactions and degradation

PostsRepliesMedia
Reposted by Alessio Ciulli
Trends in Biochemical Sciences @cp-trendsbiochem.bsky.social · 24/09/2026
🔬 In the latest #TIBS50: Foundations and frontiers installment, @alessiociulli.bsky.social and co look to proximity-inducing therapeutics and how the often-underappreciated linker can shape PROTAC function and design. Read their Feature Review: www.cell.com/trends/bioch...
011
Reposted by Alessio Ciulli
Lorraine Reese @lorraine-reese.bsky.social · 17/09/2026
Hear from our 2026 Industry and Academic Collaboration Award winner, Alessio Ciulli @alessiociulli.bsky.social, at Transcription and Chromatin UK in the beautiful medieval city of York, UK, 18-20 November. Early booking deadline is TOMORROW! 🧪 bit.ly/4eWyTmc
The Biochemical Society 2026 Awards. Industry and Academic Collaboration Award. ACBI (Alessio Ciulli - Boehringer Ingelheim) PROTAC Collaboration Team, University of Dundee, UK. Includes photo of the team, a close up photo of Alessio Ciulli, and the Biochemical Society Awards logo.
011
Reposted by Alessio Ciulli
Nature Chemical Biology @natchembio.nature.com · 15/05/2026
A new series of covalent, monovalent glue degraders can co-opt two E3 ligases, DCAF16 and FBBXO22, in a parallel fashion to degrade SMARCA2/4 with chemically and genetically tunable ligase preference www.nature.com/articles/s41...
nature.com
Dual E3 ligase recruitment by monovalent degraders for tunable SMARCA 2/4 degradation - Nature Chemical Biology
The authors identified a series of covalent, monovalent glue degraders that can co-opt two E3 ligases, DCAF16 and FBXO22, in a parallel fashion to degrade SMARCA2/4 and demonstrated that ligase prefer...
042
Reposted by Alessio Ciulli
Stephan Hacker @stephanhacker2.bsky.social · 19/11/2025
Exciting @biorxivpreprint.bsky.social by the groups of @pjcossar.bsky.social and @alessiociulli.bsky.social. They use a molecular glue between 14-3-3 and an intrinsically disordered domain of ERα to develop a molecular glue-based PROTAC recruiting VHL. doi.org/10.1101/2025... #TPD #ChemSky #ChemBio
doi.org
Induced ubiquitination of the partially disordered Estrogen Receptor alpha protein via a 14-3-3-directed molecular glue-based PROTAC design
Proteins lacking defined ligandable pockets remain challenging drug targets. Here, we develop a molecular glue-based PROTAC (MGPROTACs) approach that chemically conjugates a molecular glue stabilizer ...
1145
Reposted by Alessio Ciulli
Charlotte Crowe @charlcrowe.bsky.social · 19/11/2025
An absolute pleasure to work with all co-authors on this study: from @alessiociulli.bsky.social’s lab (the 🤝 House of VHL 🤝) @alesalerno.bsky.social & Gajanan Sathe – and our wonderful collaboration Graham Marsh and Hannah Maple from Tocris Bio-Techne
031
Reposted by Alessio Ciulli
Fusion Conferences @fusionconf.bsky.social · 12/11/2025
@alessiociulli.bsky.social we are looking forward to your presentation at our #UbiquitinFunction meeting in Portugal ☀️ Please share this with your followers to let them know you will speaking, and to register & submit today to join us! bit.ly/47DJnU2
031
Reposted by Alessio Ciulli
Eric Topol @erictopol.bsky.social · 07/05/2025
Get ready for the PROTACS, targeting proteins related to cancer and potentially other diseases a new feature @nature.com www.nature.com/articles/d41...
218244
Reposted by Alessio Ciulli
Nature Reviews Cancer @natrevcancer.nature.com · 25/04/2025
NEW content online!
nature.com
Targeted protein degradation for cancer therapy
Nature Reviews Cancer, Published online: 25 April 2025; doi:10.1038/s41568-025-00817-8Targeted protein degradation (TPD) is an emerging pharmacological modality in cancer therapy. In this Review, Hinterndorfer et al. outline the mechanistic bases of TPD and discuss the characteristics, advantages and applications of established compounds as well as upcoming classes of degraders.
0175
Alessio Ciulli @alessiociulli.bsky.social · 09/04/2025
Excited to share our latest preprint introducing BromoCatch - our cool new Tag solution for protein self-labeling inside cell. This should be a useful addition to the current arsenal of tools eg Halo, Snap. Link to the paper to catch your attention! => www.biorxiv.org/content/10.1...
biorxiv.org
BromoCatch: a self-labelling tag platform for protein analysis and live cell imaging
Visualizing and manipulating proteins in live cells is crucial for studying complex biological processes. Self-labelling protein (SLP) tags such as HaloTag and SNAP-tag can be fused to genes of intere...
1112
Alessio Ciulli @alessiociulli.bsky.social · 15/03/2025
Delighted to see this, many congratulations and fully deserved! The Boehringer foundation and your colleagues are lucky to have your vision leading this initiative. I am excited as our collaboration will thrive in your new home, and by opportunities for AITHYRA and CeTPD to work together in future
190
Reposted by Alessio Ciulli
Georg Winter @georgwinter.bsky.social · 13/03/2025
Something that qualifies as big news from my side: I am very happy and excited to announce that I have been appointed as Life Science Director at AITHYRA, a new Research Institute for Biomedical Artificial Intelligence. Find out more in the link and 🧵 below lnkd.in/d_HaGuSE
lnkd.in
LinkedIn
This link will take you to a page that’s not on LinkedIn
310611
Alessio Ciulli @alessiociulli.bsky.social · 10/03/2025
Check-out the first paper from @farnabygroup.bsky.social developing novel chemistry for plate-based PROTAC assembly that in a single Direct-to-Biology (D2B) screen delivers a potent hit that degrades the target protein in the brain of a mouse. Delighted to see this out and kudos to all co-authors
1120
Reposted by Alessio Ciulli
Women in TPD & Induced Proximity @womenintpd.bsky.social · 22/02/2025
Congratulations to our Keystone Proximity-Based Therapeutics conference travel scholarship winners Christine Ng @stanford-chemh.bsky.social and @alesalerno.bsky.social at CeTPD Dundee! @keystonesymposia.bsky.social
1113
Reposted by Alessio Ciulli
Women in TPD & Induced Proximity @womenintpd.bsky.social · 24/01/2025
Congratulations to @alesalerno.bsky.social from University of Dundee CeTPD and Christine Ng from @stanford-chemh.bsky.social who have been selected as recipients of our conference travel scholarships to attend the Proximity-based Therapeutics Keystone conference @keystonesymposia.bsky.social!
0208
Alessio Ciulli @alessiociulli.bsky.social · 07/01/2025
Collaboration with @supertifurgalab.bsky.social out in @cp-cellchembiol.bsky.social we identify a role of ABCC1 transporter in PROTAC efflux. It turns out, getting in is surprisingly not often the problem; it’s keeping it once inside the cell! Maybe some wider lessons. Designing it out could be key
2132
Alessio Ciulli @alessiociulli.bsky.social · 02/01/2025
The best way to start 2025: New Year, New Paper! Happy to see (finally!) the science of Amphista therapeutics coming out on @biorxivpreprint.bsky.social Work led by @andre-head.bsky.social and Scott Hughes and congrats to the entire Amphista team involved on the drug development and mode of action.
0120
Alessio Ciulli @alessiociulli.bsky.social · 21/12/2024
🚨 Exciting News! 🚨 What happens when unconventional ideas drive to push boundaries? 🚀 Meet FerroTACs: a novel #PROTAC design using ferrocene as core unit to re-imagining linker design and fine-tune their phys-chem properties. Learn more about our work led by @alesalerno.bsky.social here: 🧪👇 1/5
4417
Alessio Ciulli @alessiociulli.bsky.social · 08/12/2024
Happy to share our latest review on SOCS proteins and their role and therapeutic potential as targets in immunology. To date, drug discovery targeting SOCS proteins have been elusive, due to the difficulty to drug their polar SH2 domain.. 1/3 www.frontiersin.org/journals/imm...
frontiersin.org
Frontiers | Unravelling the druggability and immunological roles of the SOCS-family proteins
1111
Reposted by Alessio Ciulli
Derek Lowe @dereklowe.bsky.social · 03/12/2024
That awkward moment when someone publishes a paper saying that they can’t find any evidence that your compounds bind to what your own series of papers say that they bind to. . .
science.org
Do They Even Bind?
910726
Alessio Ciulli @alessiociulli.bsky.social · 03/12/2024
So privileged that CHI-Healthtech brought their flagship #DDC conference to Europe, in sunny ☀️ Barcelona! Enjoying tapas and sangria with Heide Düvel @chemb.bsky.social @rpnowak.bsky.social Gopal Sapkota, Ed Tate @nurkocaturk.bsky.social Hannah Peters, Rima Alawar. Thanks for the invitation Tanuja!
3103
Alessio Ciulli @alessiociulli.bsky.social · 03/12/2024
Nice write-up of the successful SMART TPD symposium in Shenzhen, China - co-organised with Nat Gray, Nieng Yan, Peng Chan and Shixiang Yan. So enjoyed the opportunity. #TPD #SMARTsymposia www.szbl.ac.cn/en/infomatio...
1153
Reposted by Alessio Ciulli
Woody Sherman @woody-sherman.bsky.social · 26/11/2024
Just announced: 2025 Computer-Aided Drug Design (CADD) GRC program The topic: "Exploring the Synergy of Machine Learning and Physics-Based Computational Chemistry to Accelerate Drug Discovery" It is shaping up to be a seminal conference. Hope to see you there! www.grc.org/computer-aid...
grc.org
2025 Computer Aided Drug Design Conference GRC
The 2025 Gordon Research Conference on Computer Aided Drug Design will be held in Portland, Maine. Apply today to reserve your spot.
25213
Alessio Ciulli @alessiociulli.bsky.social · 01/12/2024
Sooo hilarious yet true!! 😂🤣
130
Alessio Ciulli @alessiociulli.bsky.social · 30/11/2024
Leveraging Dual-Ligase Recruitment to Enhance Protein Degradation via a Heterotrivalent Proteolysis Targeting Chimera | Collaboration with @georgwinter.bsky.social and Kristin Riching labs. Now published in Journal of the American Chemical Society @acsjacs.bsky.social pubs.acs.org/doi/10.1021/...
pubs.acs.org
Leveraging Dual-Ligase Recruitment to Enhance Protein Degradation via a Heterotrivalent Proteolysis Targeting Chimera
Proteolysis targeting chimera (PROTAC) degraders are typically bifunctional with one E3 ligase ligand connected to one target protein ligand via a linker. While augmented valency has been shown with t...
25513
Reposted by Alessio Ciulli
Georg Winter @georgwinter.bsky.social · 28/11/2024
Dual-ligase PROTACs: a novel approach for enhancing TPD. By recruiting two distinct E3 ligases within a single molecule, we amplify degradation efficacy & potentially mitigate resistance occurrence. Great collabo with the Ciulli lab & friends at Promega. pubs.acs.org/doi/10.1021/...
pubs.acs.org
Leveraging Dual-Ligase Recruitment to Enhance Protein Degradation via a Heterotrivalent Proteolysis Targeting Chimera
Proteolysis targeting chimera (PROTAC) degraders are typically bifunctional with one E3 ligase ligand connected to one target protein ligand via a linker. While augmented valency has been shown with trivalent PROTACs targeting two binding sites within a given target protein, or used to recruit two different targets, the possibility of recruiting two different E3 ligases within the same compound has not been demonstrated. Here we present dual-ligase recruitment as a strategy to enhance targeted protein degradation. We designed heterotrivalent PROTACs composed of CRBN, VHL and BET targeting ligands, separately tethered via a branched trifunctional linker. Structure–activity relationships of 12 analogues qualifies AB3067 as the most potent and fastest degrader of BET proteins, with minimal E3 ligase cross-degradation. Comparative kinetic analyses in wild-type and ligase single and double knockout cell lines revealed that protein ubiquitination and degradation induced by AB3067 was contributed to by both CRBN and VHL in an additive fashion. We further expand the scope of the dual-ligase approach by developing a heterotrivalent CRBN/VHL-based BromoTag degrader and a tetravalent PROTAC comprising of two BET ligand moieties. In summary, we provide proof-of-concept for dual-E3 ligase recruitment as a strategy to boost degradation fitness by recruiting two E3 ligases with a single degrader molecule. This approach could potentially delay the outset of resistance mechanisms involving loss of E3 ligase functionality.
14711
Alessio Ciulli @alessiociulli.bsky.social · 26/11/2024
So proud of my former PhD student Tom Webb who defended his thesis with flying colors yesterday! Many thanks to @robvanmontfort.bsky.social from the ICR and Beatriz Baragana from our own Dundee DDU. Also great to host Johan Johansson from AZ it was great to have you visiting us!
Alessio, Tom and Johan post-Viva!The big card!
150
Alessio Ciulli @alessiociulli.bsky.social · 26/11/2024
Hi everyone! I’m excited to joining this community at @bsky.app BlueSky Social and temperature-test this over the next few months! Looking forward to connecting and sharing with many of you here!
091